# Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity

**Authors:** Malgorzata Wachowska, Angelika Muchowicz, Jakub Golab

PMC · DOI: 10.3389/fonc.2015.00176 · 2015-07-30

## TL;DR

This review explores how combining photodynamic therapy with epigenetic treatments can enhance anticancer immunity by restoring immune recognition of tumor cells.

## Contribution

The paper introduces how epigenetic treatments, like methyltransferase inhibitors, can boost PDT's effectiveness by reactivating immune-related genes.

## Key findings

- Epigenetic treatments can restore expression of silenced major histocompatibility complex molecules and tumor-associated antigens.
- Combining PDT with methyltransferase inhibitors enhances antitumor immunity and improves therapeutic outcomes.
- Epigenetic regulation plays a key role in tumor immune evasion and can be targeted to improve immunotherapy.

## Abstract

Photodynamic therapy (PDT) of cancer is an approved therapeutic procedure that generates oxidative stress leading to cell death of tumor and stromal cells. Cell death resulting from oxidative damage to intracellular components leads to the release of damage-associated molecular patterns (DAMPs) that trigger robust inflammatory response and creates local conditions for effective sampling of tumor-associated antigens (TAA) by antigen-presenting cells. The latter can trigger development of TAA-specific adaptive immune response. However, due to a number of mechanisms, including epigenetic regulation of TAA expression, tumor cells evade immune recognition. Therefore, numerous approaches are being developed to combine PDT with immunotherapies to allow development of systemic immunity. In this review, we describe immunoregulatory mechanisms of epigenetic treatments that were shown to restore the expression of epigenetically silenced or down-regulated major histocompatibility complex molecules as well as TAA. We also discuss the results of our recent studies showing that epigenetic treatments based on administration of methyltransferase inhibitors in combination with PDT can release effective mechanisms leading to development of antitumor immunity and potentiated antitumor effects.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** Ccl17 (C-C motif chemokine ligand 17) [NCBI Gene 20295] {aka Abcd-2, Scya17, Scya17l, Tarc}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, B2m (beta-2 microglobulin) [NCBI Gene 12010] {aka Ly-m11, beta2-m, beta2m}, Bcl2l1 (BCL2-like 1) [NCBI Gene 12048] {aka Bcl(X)L, Bcl-XL, Bcl2l, BclX, bcl-x, bcl2-L-1}, Lag3 (lymphocyte-activation gene 3) [NCBI Gene 16768] {aka CD223, LAG-3, Ly66}, Trav6-3 (T cell receptor alpha variable 6-3) [NCBI Gene 328483] {aka Gm13948, Gm193, Gm4, TCR}, Zfp185 (zinc finger protein 185) [NCBI Gene 22673] {aka P1, Znf185}, Ido1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 15930] {aka Ido, Indo}, Tnfrsf10b (tumor necrosis factor receptor superfamily, member 10b) [NCBI Gene 21933] {aka DR5, KILLER, Ly98, MK, TRAILR2, TRICK2A}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, Hspa1b (heat shock protein family A (Hsp70) member 1B) [NCBI Gene 15511] {aka HSP70B1, Hsp70, Hsp70-1, Hsp70.1, hsp68}, Csf3 (colony stimulating factor 3 (granulocyte)) [NCBI Gene 12985] {aka Csfg, G-CSF, MGI-IG}, Mill2 (MHC I like leukocyte 2) [NCBI Gene 243864] {aka Micb}, Fasl (Fas ligand) [NCBI Gene 14103] {aka APT1LG1, CD178, CD95-L, CD95L, Fas-L, Faslg}, Glb1 (galactosidase, beta 1) [NCBI Gene 12091] {aka Bge, Bgl, Bgl-e, Bgl-s, Bgl-t, Bgs}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, SSX2B (SSX family member 2B) [NCBI Gene 727837] {aka CT5.2, CT5.2b, HOM-MEL-40, SSX}, Pdcd1lg2 (programmed cell death 1 ligand 2) [NCBI Gene 58205] {aka B7-DC, Btdc, F730015O22Rik, PD-L2}, Ctla4 (cytotoxic T-lymphocyte-associated protein 4) [NCBI Gene 12477] {aka Cd152, Ctla-4, Ly-56}, Tap1 (transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)) [NCBI Gene 21354] {aka ABC17, APT1, Abcb2, Ham-1, Ham1, MTP1}, Cflar (CASP8 and FADD-like apoptosis regulator) [NCBI Gene 12633] {aka 2310024N18Rik, A430105C05Rik, CLARP, Cash, Casper, FLAME}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Vsir (V-set immunoregulatory receptor) [NCBI Gene 74048] {aka 4632428N05Rik, Dies1, PD-1H, VISTA}, PSMB9 (proteasome 20S subunit beta 9) [NCBI Gene 5698] {aka LMP2, PRAAS3, PRAAS6, PSMB6i, RING12, beta1i}, Stat6 (signal transducer and activator of transcription 6) [NCBI Gene 20852], Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Tap2 (transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)) [NCBI Gene 21355] {aka ABC18, APT2, Abcb3, Ham-2, Ham2, MTP2}, Canx (calnexin) [NCBI Gene 12330] {aka 1110069N15Rik, Cnx, D11Ertd153e}, ZNF185 (zinc finger protein 185 with LIM domain) [NCBI Gene 7739] {aka SCELL}, PSMB10 (proteasome 20S subunit beta 10) [NCBI Gene 5699] {aka IMD121, LMP10, MECL1, PRAAS5, beta2i}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, TAP1 (transporter 1, ATP binding cassette subfamily B member) [NCBI Gene 6890] {aka ABC17, ABCB2, APT1, D6S114E, MHC1D1, PSF-1}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}, Inhca (inhibitor of carbonic anhydrase) [NCBI Gene 71775] {aka 1300017J02Rik, Ica, mICA}, Tapbp (TAP binding protein) [NCBI Gene 21356] {aka D17Wsu91e, TPN}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Ccr7 (C-C motif chemokine receptor 7) [NCBI Gene 12775] {aka CC-CKR-7, CCR-7, CD197, Cdw197, Cmkbr7, EBI1}, ANPEP (alanyl aminopeptidase, membrane) [NCBI Gene 290] {aka AP-M, AP-N, APN, CD13, GP150, LAP1}, Cxcl2 (C-X-C motif chemokine ligand 2) [NCBI Gene 20310] {aka CINC-2a, GROb, Gro2, MIP-2, MIP-2a, Mgsa-b}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, CIITA (class II major histocompatibility complex transactivator) [NCBI Gene 4261] {aka C2TA, CIITAIV, MHC2D1, MHC2TA, NLRA}, Psmb9 (proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)) [NCBI Gene 16912] {aka Lmp-2, Lmp2, Ring12}, Calr (calreticulin) [NCBI Gene 12317] {aka CRT, Calregulin}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Hsp84-3 (heat shock protein, 3) [NCBI Gene 104434] {aka 84kDa, Hsp90, hsp3}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Havcr2 (hepatitis A virus cellular receptor 2) [NCBI Gene 171285] {aka TIM-3, Tim3, Timd3}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Psmb8 (proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)) [NCBI Gene 16913] {aka Lmp-7, Lmp7}, CTAG1A (cancer/testis antigen 1A) [NCBI Gene 246100] {aka CT6.1, ESO1, LAGE-2, LAGE2A, NY-ESO-1}
- **Diseases:** colon adenocarcinomas (MESH:D003110), breast cancer (MESH:D001943), cytotoxic (MESH:D064420), hematologic malignancies (MESH:D019337), TAA (MESH:C535887), Cancer (MESH:D009369), mast cell-mastocytoma 815 (MESH:D000090362), necrotic (MESH:D009336), LLC lung carcinomas (MESH:D008175), VIN (MESH:D002578), metastases (MESH:D009362), angiosarcoma (MESH:D006394), CTA (MESH:D013736), immunodeficient (MESH:D007153), inflammation (MESH:D007249), melanoma (MESH:D008545), mammary tumors (MESH:D015674), Basal cell carcinoma (MESH:D002280), fibrosarcoma (MESH:D005354)
- **Chemicals:** oxygen (MESH:D010100), 5-methylcytosine (MESH:D044503), silica (MESH:D012822), tryptophan (MESH:D014364), hydroxyl radical (MESH:D017665), 5-aza-2'-deoxicitidyne (-), hydrogen peroxide (MESH:D006861), kynurenine (MESH:D007737), ATP (MESH:D000255), superoxide ion (MESH:D013481), Vorinostat (MESH:D000077337), chitosan (MESH:D048271), singlet oxygen (MESH:D026082), cholesterol (MESH:D002784), amino acids (MESH:D000596), TCA (MESH:C012589), ROS (MESH:D017382)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** C5 of cytosine
- **Cell lines:** CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), EMT6 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_1923), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4519687/full.md

---
Source: https://tomesphere.com/paper/PMC4519687